Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pyridoxine 80mg/5ml oral solution
0906024N0AACHCH
|
Pyridoxine hydrochloride | Pyridoxine hydrochloride | Nutrition and Blood | No data available |
|
Pyridoxine 90mg/5ml oral solution
0906024N0AACNCN
|
Pyridoxine hydrochloride | Pyridoxine hydrochloride | Nutrition and Blood | No data available |
|
Pyrimethamine 10mg/5ml oral suspension
0504010N0AAAIAI
|
Pyrimethamine | Pyrimethamine | Infections | No data available |
|
Pyrimethamine 25mg / Sulfadoxine 500mg tablets
0504010P0AAAAAA
|
Pyrimethamine/sulfadoxine | Pyrimethamine with sulfadoxine | Infections | No data available |
|
Pyrimethamine 25mg/5ml oral suspension
0504010N0AAAFAF
|
Pyrimethamine | Pyrimethamine | Infections | No data available |
|
Pyrimethamine 5mg/5ml oral suspension
0504010N0AAAEAE
|
Pyrimethamine | Pyrimethamine | Infections | No data available |
|
Pyrimethamine 7.5mg/5ml oral suspension
0504010N0AAAGAG
|
Pyrimethamine | Pyrimethamine | Infections | No data available |
|
Pyrimethamine 9mg/5ml oral suspension
0504010N0AAAHAH
|
Pyrimethamine | Pyrimethamine | Infections | No data available |
|
Pyrocalm Control 20mg gastro-resistant tablets
0103050P0BHAABD
|
Pyrocalm Control | Omeprazole | Gastro-Intestinal System | No data available |
|
Pyrogastrone chewable tablets
0103060E0BBABAB
|
Pyrogastrone | Carbenoxolone sodium compound preparations | Gastro-Intestinal System | No data available |
|
Pyrogastrone oral suspension
0103060E0BBAAAA
|
Pyrogastrone | Carbenoxolone sodium compound preparations | Gastro-Intestinal System | No data available |
|
Pyzchiva 130mg/26ml concentrate for inf vials
0105030B0BCAAAA
|
Pyzchiva | Ustekinumab | Gastro-Intestinal System | No data available |
|
Pyzchiva 45mg/0.5ml inj pre-filled syringes
1305030D0BCACAB
|
Pyzchiva | Ustekinumab | Skin | No data available |
|
Pyzchiva 90mg/1ml solution for injection pre-filled syringes
1305030D0BCABAC
|
Pyzchiva | Ustekinumab | Skin | No data available |
|
Qaialdo 10mg/ml oral suspension
0202030S0BLAAEB
|
Qaialdo | Spironolactone | Cardiovascular System | No data available |
|
Quadrivalent influenza vacc (live attenuated) nsl susp 0.2ml
1404000H0AAAJAJ
|
Influenza | Influenza | Immunological Products and Vaccines | No data available |
|
Quadrivalent influenza vaccine (rcmb) inj 0.5ml pfs
1404000H0AAAPAP
|
Influenza | Influenza | Immunological Products and Vaccines | No data available |
|
Quellada-M 0.5% liquid
1310040M0BEABAD
|
Quellada-M | Malathion | Skin | No data available |
|
Quellada-M 1% cream shampoo
1310040M0BEAAAB
|
Quellada-M | Malathion | Skin | No data available |
|
Quest Bilberry Extract 60mg tablets
091200000BEPWA0
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
Quest Cell Life tablets
091000000BBKWBU
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
Quest Cod Liver Oil 1000mg capsules
0906011H0BTAAAG
|
Quest Cod Liver Oil | Cod liver oil | Nutrition and Blood | No data available |
|
Quest DL-Phenylalanine 500mg capsules
091101000BBLXA0
|
Proprietary compound preparation BNF 0911010 | Other amino acidandnutritional agent preparations | Nutrition and Blood | No data available |
|
Quest Enzyme Digest tablets
091102000BBACA0
|
Proprietary compound preparation BNF 0911020 | Other enzyme preparations 0911020 | Nutrition and Blood | No data available |
|
Quest Glucosamine sulfate 1000mg tablets
091200000BFQADY
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.